Research Topics
| Maura N DicklerSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancerMaura N Dickler
Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Breast Cancer Res Treat 115:115-21. 2009..Cohort 2: progression after >1 chemotherapy for advanced-stage disease (n = 22). Primary endpoint was response rate (World Health Organization criteria). Secondary endpoints were safety, time to progression, and survival...
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancerMaura N Dickler
Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 14:7878-83. 2008..To evaluate the efficacy and toxicity of erlotinib plus bevacizumab in patients with metastatic breast cancer (MBC), targeting the epidermal growth factor receptor (EGFR/HER1) and the vascular endothelial growth factor (VEGF) pathway...
Do biomarker changes during neoadjuvant endocrine therapy reflect breast tumor receptor status?Maura Dickler
Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Nat Clin Pract Oncol 2:498-9. 2005- Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancerTiffany A Traina
Breast Cancer Medicine Service, Departments of Radiology, Biostatistics, and Renal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 28:628-33. 2010..We therefore performed a feasibility study to evaluate the safety of letrozole plus bevacizumab in patients with hormone receptor-positive metastatic breast cancer (MBC)... - Bevacizumab for advanced breast cancerShari B Goldfarb
Breast Cancer Medicine Service, Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Womens Health (Lond Engl) 6:17-25. 2010..This review article discusses the clinical trials establishing the use of bevacizumab for the treatment of advanced breast cancer... - A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancerHeather L McArthur
Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
Clin Cancer Res 17:3398-407. 2011..We evaluated the cardiac safety of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (ddAC) → nanoparticle albumin-bound (nab)-paclitaxel in human epidermal growth factor receptor 2 normal early-stage breast cancer... - Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imagingValencia King
Department of Radiology, Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Radiology 264:670-8. 2012.... - Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancerChau T Dang
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Clin Cancer Res 10:5754-61. 2004..The primary objective was to determine the feasibility of the regimen; the secondary objective was to estimate the disease-free and overall survival... - When you look matters: the effect of assessment schedule on progression-free survivalKatherine S Panageas
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd St, 3rd Fl, New York, NY 10021, USA
J Natl Cancer Inst 99:428-32. 2007..The decision to use PFS as a primary endpoint should be made carefully when designing clinical trials, and investigators focused on a particular disease should develop consensus standards and strive for consistent surveillance intervals... - Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatmentsChau T Dang
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
Clin Cancer Res 10:4062-7. 2004..CONCLUSIONS: Celecoxib combined with trastuzumab is well tolerated. However, this combination in patients with HER2/neu-overexpressing, trastuzumab-refractory disease, was not active... - Aromatase inhibitors for hormonal therapy of early-stage breast cancerTiffany A Traina
Memorial Sloan Kettering Cancer Center, Department of Medicine, Breast Cancer Medicine Service, 1275 York Avenue, New York, NY 10021, USA
Curr Opin Investig Drugs 5:605-10. 2004..This review focuses on data on aromatase inhibitors in the adjuvant setting and looks to the future potential of these drugs in both ductal carcinoma in situ and chemoprevention... - Biomarkers in breast cancerHeather L McArthur
Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Cancer Biol Ther 7:21-2. 2008 - Characteristics of oral mucosal events related to bevacizumab treatmentIgor T Gavrilovic
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10022, USA
Oncologist 17:274-8. 2012..We aimed at providing a detailed clinical description of signs and symptoms limited to the tongue mucosa in patients treated with bevacizumab... - Bevacizumab in metastatic breast cancer: when may it be used?Shari B Goldfarb
Memorial Sloan Kettering Cancer Center, Medicine and Epidemiology and Biostatistics, New York, NY, USA
Ther Adv Med Oncol 3:85-93. 2011..In this article we review the clinical trials testing the utility of bevacizumab for the treatment of metastatic disease... - Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100Bryan P Schneider
Indiana University School of Medicine, Indianapolis, IN, USA
J Clin Oncol 26:4672-8. 2008..Therefore, we evaluated the association of VEGF genotype with efficacy and toxicity in E2100, a phase III study comparing paclitaxel versus paclitaxel plus bevacizumab as initial chemotherapy for metastatic breast cancer... - The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancerChau Dang
Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 713, New York, NY 10021, USA
J Clin Oncol 26:1216-22. 2008..The primary end point was cardiac safety, and the secondary end points were time to recurrence and overall survival... - Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancerKathy Miller
Indiana University Cancer Center, Indianapolis, USA
N Engl J Med 357:2666-76. 2007.... - Bevacizumab for advanced breast cancerTiffany A Traina
Department of Medicine, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Hematol Oncol Clin North Am 21:303-19. 2007..In this article the authors discuss the data pertaining to bevacizumab and other antiangiogenic agents for the treatment of patients who have advanced breast cancer... - Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21Teresa A Gilewski
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 13:2977-85. 2007..To determine the clinical toxicities and antibody response against sTn and tumor cells expressing sTn following immunization of high-risk breast cancer patients with clustered sTn-KLH [sTn(c)-KLH] conjugate plus QS-21... - A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancerShanu Modi
Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Breast Cancer Res Treat 90:157-63. 2005..CONCLUSION: Imatinib therapy at doses of 800 mg/day was associated with significant toxicity in patients with heavily pre-treated MBC. Our results do not indicate activity for imatinib monotherapy in these unselected patients... - Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancerKathy D Miller
Indiana University, Indianapolis, IN, USA
J Clin Oncol 23:792-9. 2005.... - Multicenter phase II study of oral bexarotene for patients with metastatic breast cancerFrancisco J Esteva
University of Texas M D Anderson Cancer Center, and Baylor College of Medicine, Houston, Texas 77030, USA
J Clin Oncol 21:999-1006. 2003..However, it is an oral agent with minimal toxicity and a unique mechanism of action, which produced clinical benefit in approximately 20% of patients. Future efforts should define populations likely to benefit from this agent...